SiDanSai Biotechnology

Sidansai Biotechnology, operating internationally as Innovative Cellular Therapeutics (ICT), is a clinical-stage biotechnology company focused on developing advanced Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company leverages its proprietary CoupledCAR platform technology, which is specifically designed to overcome the immunosuppressive microenvironment of solid tumors by enhancing CAR-T cell expansion and infiltration. Their pipeline includes several candidates targeting both hematological malignancies and difficult-to-treat solid tumors such as liver, ovarian, and colorectal cancers. Headquartered in Shanghai with a significant clinical and regulatory presence in the United States, Sidansai is positioned as a leader in the next generation of cell-based immunotherapy.